Research Article

Comprehensive Analysis of Perioperative Anaesthesia Concerns in Covid Associated Mucormycosis: A Retrospective Study of Surgical Patients


Background: Data regarding sudden surge of mucormycosis cases with COVID-19 outbreak and its impact on anaesthesia management are lacking. This retrospective study was designed to analyze the number and characteristics of patients posted for mucormycosis surgery in COVID19 pandemic while emphasizing upon the anaesthesia concerns.
Methods: Data was collected from all patients who were admitted with mucormycosis in our institute from the year 2020 onwards. Further analysis of patients who were surgically treated was carried out in terms of demographic characteristics, association with COVID19 and perioperative course of mucormycosis and anaesthetic management. All statistical analyses were performed with the Statistical package for social sciences (SPSS) version 25·0 software.
Results: We report an incidence of 30 operated patients of the average age 52.60 years with mucormycosis from August 2020 to May 2021. Diabetes as a comorbidity was common (86.90%).  Previous infection with COVID-19 was observed in 29 (96.60%) out of which 80% patients had residual pulmonary involvement. Concomitant medical therapy with Amphotericin B was received by 90% patients and subsequently 70% had deranged renal profile. While 20 % patients had compromised airway, 60 % required blood transfusion and 76.6% patients were electively ventilated while 1 patient (3.3%) succumbed amounting to a survival rate of 96.6%.
Conclusion: To conclude elderly male diabetic patients with history of COVID19 infection is the most vulnerable population for developing mucormycosis. Airway management, glycemic control, concomitant Amphotericin B therapy and intraoperative bleeding are the major challenges for anaesthesiologist along with an element of post Covid respiratory compromise.

[1] Kulkarni PK, Reddy NB, Shrinivas B, Takkalki VV. Anesthetic considerations in the management of mucormycosis. Int J Med Public Health 2015; 5:387-90.
[2] Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARSCoV-2 infected patients. EBioMedicine. 2020; 55:102763
[3] Mehta S, Pandey A. Rhino-Orbital Mucormycosis Associated With COVID-19. Cureus. 2020; 12(9): 10726.
[4] Karaaslan E. Anesthetic management of rhinoorbitocerebral mucormycosis; Focus on challenges. J Mycol Med. 2019; 29(3):219-222.
[5] Peng M, Meng H, Sun Y, Xiao Y, Zhang H, Lv K, et al. Clinical features of pulmonary mucormycosis in patients with different immune status. J Thorac Dis. 2019; 11(12):5042–52. 4.
[6] Werth manEhrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID19. Am J Emerg Med. 2021; 42:264.e5-264.e8.
[7] RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19–preliminary report. N Engl J Med. 2021; 384(8):693-704.
[8] Sen. M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a Viral Land: A Tale of Two Pathogens. Indian J Ophthalmol. 2021; 69(2):244-52.
[9] Afroze SN, KorleparaR, Rao GV, Madala J. Mucormycosis in a diabetic patient: A case report with an insight into its pathophysiology. Contemp Clin Dent. 2017; 8(4):662-6.
[10] George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A, Forrest I, et al Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020; 75(11):1009-1016.
[11] Zhao YM, Shang YM, Song WB, Li QQ, Xie H, Xu QF, et al. Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery. EClinicalMedicine. 2020; 25100463.
[12] Banik J, Mezera V, Köhler C, Schmidtmann M. Antiplatelet therapy in patients with Covid-19: A retrospective observational study. Thrombosis Update. 2021; 2:100026.
[13] Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, et al. Neurologic features in severe SARSCoV-2 infection. New Engl J Med. 2020; 382(23):2268–70.
[14] Yusuff H, Zochios V, Brodie D. Thrombosis and Coagulopathy in COVID-19 Patients Requiring Extracorporeal Membrane Oxygenation. ASAIO J. 2020; 66(8):844-846.
[15] Eckmann DM, Seligman I, Cote´ CJ, Hussong JW. Mucormycosissupraglottitis on induction of anesthesia in an immunocompromised host. AnesthAnalg. 1998; 86:729-30.
[16] Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis:an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019; 19(12):e405–21.
[17] Choleva AJ. Anesthetic management for lobectomy in a patient withcoccidioidomycosis: A case report. AANA J 2010; 78(4):321-5.
[18] Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008; 47(4):503–9.
IssueVol 8 No 1 (2022): Winter QRcode
SectionResearch Article(s)
COVID-19 diabetes mellitus mucormycosis. Anaesthesia

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Ghodki P, Panse N, Sardesai S. Comprehensive Analysis of Perioperative Anaesthesia Concerns in Covid Associated Mucormycosis: A Retrospective Study of Surgical Patients. Arch Anesth & Crit Care. 2022;8(1):18-24.